World leader in product lifecycle management software, Dassault Systèmes, has done better than weather the health crisis; the group has just published this morning a turnover up 11% to 4.45 billion euros, in 2020 and a net profit which remains solid at 491 million euros despite a decrease of 20%. Its operating margin remains impressive at 36% (+ 2.3%)According to Pascal Daloz, Managing Director, Dassault’s results demonstrate “the extreme resilience of our economic model”, because the group has retained all of its employees, increased its research and development spending, and has not requested government aid.The software leader has particularly benefited from the explosion of its revenues in the healthcare sector, which tripled to 797 million euros, mainly thanks to the subsidiary Medidata acquired in 2019.Almost all of the vaccine producers (Pfizer / BioNTech, Moderna, AstraZeneca) have used solutions from Dassault Syst. to develop their different vaccines.In total, Dassault Systèmes software is present in “more than 500 developments of vaccines or therapies linked to Covid 19 at the moment”, specified Pascal DalozIn addition, the group has raised its forecasts of net earnings per share (EPS) from 4.10 to 4.15 euros, i.e. growth of between 8% and 10%.On the stock market, the stock reached a new all-time high this morning on the announcement of its results, it is already up 8.4% since the start of the year!